Return on Equity (ROE): 13.90%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 13.90% is 23% below its 5-year average of 18.07%, near the low end of its 5-year range (12.85%–30.96%).
As of Friday, June 26, 2026. 4.16% above its 12-month average of 13.34%.
DGX Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
DGX Average Return on Equity (ROE) Chart
DGX Current vs Average Return on Equity (ROE) Chart
DGX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
13.90%
RETURN ON EQUITY (ROE) AVG TTM
13.34%
RETURN ON EQUITY (ROE) AVG 3Y
14.07%
RETURN ON EQUITY (ROE) AVG 5Y
18.07%
RETURN ON EQUITY (ROE) AVG 10Y
16.59%
RETURN ON EQUITY (ROE) AVG 15Y
14.40%
RETURN ON EQUITY (ROE) AVG 20Y
15.69%
CURRENT VS TTM AVG
+4.16%
CURRENT VS 3Y AVG
-1.21%
CURRENT VS 5Y AVG
-23.07%
CURRENT VS 10Y AVG
-16.22%
CURRENT VS 15Y AVG
-3.50%
CURRENT VS 20Y AVG
-11.40%
DGX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $22.83B | 13.90% | 13.34% | 14.07% | 18.07% |
| BioNTech SE (BNTX)vs › | $22.76B | -6.79% | -4.55% | 10.63% | 21.70% |
| United Therapeutics Corporation (UTHR)vs › | $23.07B | 21.82% | 18.68% | 17.25% | 16.03% |
| Moderna, Inc. (MRNA)vs › | $23.71B | -43.12% | -32.64% | -13.90% | 0.25% |
| Labcorp Holdings Inc. (LH)vs › | $21.83B | 10.79% | 9.71% | 9.35% | 12.84% |
| Incyte Corporation (INCY)vs › | $21.48B | 25.79% | 12.92% | 11.29% | 9.83% |
| Waters Corporation (WAT)vs › | $24.57B | 2.94% | 29.98% | 64.02% | 111.55% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| STERIS plc (STE)vs › | $20.52B | 10.89% | 10.12% | 7.00% | 7.00% |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 12.89% | 12.42% | 12.32% | 13.45% |
Return Analysis
ROE
13.9%
ROA
6.1%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The return on equity (ROE) for DGX stock is 13.90%.
- Is Quest Diagnostics Incorporated's return on equity (ROE) high or low?
- The return on equity (ROE) of 13.90% is 23% below its 5-year average of 18.07%, near the low end of its 5-year range (12.85%–30.96%).
- What is the TTM average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The TTM average return on equity (ROE) for DGX stock is 13.34%.
- What is the 3Y average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The 3Y average return on equity (ROE) for DGX stock is 14.07%.
- What is the 5Y average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The 5Y average return on equity (ROE) for DGX stock is 18.07%.
- What is the 10Y average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The 10Y average return on equity (ROE) for DGX stock is 16.59%.
- What is the 15Y average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The 15Y average return on equity (ROE) for DGX stock is 14.40%.
- What is the 20Y average return on equity (ROE) for Quest Diagnostics Incorporated (DGX)?
- The 20Y average return on equity (ROE) for DGX stock is 15.69%.
DGX Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 13.84% |
| 2024-12-31 | 12.85% |
| 2023-12-31 | 13.54% |
| 2022-12-31 | 16.05% |
| 2021-12-31 | 30.96% |
| 2020-12-31 | 21.17% |
| 2019-12-31 | 15.21% |
| 2018-12-31 | 14.11% |
| 2017-12-31 | 15.69% |
| 2016-12-31 | 13.94% |
| 2015-12-31 | 15.14% |
| 2014-12-31 | 12.93% |
| 2013-12-31 | 21.50% |
| 2012-12-31 | 13.35% |
| 2011-12-31 | 12.74% |
| 2010-12-31 | 17.87% |
| 2009-12-31 | 18.28% |
| 2008-12-31 | 16.13% |
| 2007-12-31 | 10.23% |
| 2006-12-31 | 19.42% |
| 2005-12-31 | 19.77% |
| 2004-12-31 | 21.81% |
| 2003-12-31 | 18.24% |
| 2002-12-31 | 18.21% |
| 2001-12-31 | 12.15% |
| 2000-12-31 | 9.89% |
| 1999-12-31 | -0.39% |
| 1998-12-31 | 4.74% |
| 1997-12-31 | -4.12% |
| 1996-12-31 | -116.19% |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis